| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received September 15, 2005
Accepted on January 3, 2006
ORIGINAL ARTICLES |
Royal Melbourne Hospital, Parkville, Victoria, Australia
1 To whom correspondence should be addressed. E-mail: anastasiac{at}optusnet.com.au.
 |
Abstract |
|---|
Studies have shown that dual therapy with angiotensin-converting enzyme inhibitors (ACEI) and either angiotensin II receptor blockers or aldosterone receptor antagonists is more effective in reducing proteinuria than either agent used alone. The questions that remain are as follows: (1) Which of these agents should be used as dual therapy with the ACEI? (2) Does a higher level of blockade of the renin-angiotensin-aldosterone system with triple therapy offer an advantage over dual blockade? A 3-mo randomized, double-blind, placebo-controlled study was performed in 41 patients with proteinuria >1.5 g/d. Four treatment groups were compared: (1) Ramipril + spironolactone placebo + irbesartan placebo, (2) ramipril + irbesartan + spironolactone placebo, (3) ramipril + irbesartan placebo + spironolactone, and (4) ramipril + irbesartan + spironolactone. The percentage change in protein excretion differed according to treatment arm (ANOVA: F3,35 = 8.6, P < 0.001). Pair-wise comparison showed that greater reduction in protein excretion occurred in treatment regimens that incorporated spironolactone. The reduction in proteinuria at 3 mo was as follows: Group 1, 1.4%; group 2, 15.7%; group 3, 42.0%; and group 4, 48.2%. The reduction in proteinuria among patients who were taking spironolactone-containing regimens was sustained at 6 and 12 mo. This study suggests that aldosterone receptor blockade offers a valuable adjuvant treatment when used with ACEI therapy for the reduction of proteinuria. Results suggest no advantage of triple blockade over dual blockade of the renin-angiotensin-aldosterone system to reduce proteinuria.
This article has been cited by other articles:
|
|
 |
|
  V. Ramirez, J. Trujillo, R. Valdes, N. Uribe, C. Cruz, G. Gamba, and N. A. Bobadilla Adrenalectomy prevents renal ischemia-reperfusion injury Am J Physiol Renal Physiol, October 1, 2009; 297(4): F932 - F942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Haynes, P. Mason, K. Rahimi, and M. J Landray Dual blockade of the renin-angiotensin system: are two better than one? Nephrol. Dial. Transplant., September 17, 2009; (2009) gfp458v1. [Full Text] [PDF]
|
|
|
|
|
|
G. J. Becker, T. D. Hewitson, and A. Chrysostomou Aldosterone in clinical nephrology--old hormone, new questions Nephrol. Dial. Transplant., August 1, 2009; 24(8): 2316 - 2321. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cortinovis, N. Perico, D. Cattaneo, and G. Remuzzi Aldosterone and progression of kidney disease Therapeutic Advances in Cardiovascular Disease, April 1, 2009; 3(2): 133 - 143. [Abstract] [PDF]
|
|
|
|
 |
|
 S. D. Navaneethan, S. U. Nigwekar, A. R. Sehgal, and G. F.M. Strippoli Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease: A Systematic Review and Meta-analysis Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 542 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Saran and T. D. DuBose Jr Cardiovascular disease in chronic kidney disease Therapeutic Advances in Cardiovascular Disease, December 1, 2008; 2(6): 425 - 434. [Abstract] [PDF]
|
|
|
|
 |
|
 S. HIRSCH An update on proteinuric chronic kidney disease: The dual-goal approach Cleveland Clinic Journal of Medicine, October 1, 2008; 75(10): 705 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Panesar, A. Damodar, T. Lindner, S. Anderson, R. Komers, K. Kamoi, H.-H. Parving, and F. Persson Aliskiren combined with losartan in diabetes and nephropathy. N. Engl. J. Med., September 4, 2008; 359(10): 1068 - 1069. [Full Text] [PDF]
|
|
|
|
|
|
G. Piecha, N. Koleganova, M.-L. Gross, A. Geldyyev, M. Adamczak, and E. Ritz Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination Am J Physiol Renal Physiol, July 1, 2008; 295(1): F137 - F144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Steigerwalt Management of Hypertension in Diabetic Patients With Chronic Kidney Disease Diabetes Spectr, January 1, 2008; 21(1): 30 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Karara, V. Hanes, A. Alonso, P. Ni, N. Poola, R. Silang, H. Blode, and R. A. Preston Pharmacokinetics and Pharmacodynamics of Drospirenone-Estradiol Combination Hormone Therapy Product Coadministered With Hydrochlorothiazide in Hypertensive Postmenopausal Women J. Clin. Pharmacol., October 1, 2007; 47(10): 1292 - 1302. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
